MassBio

“Revolutions create change. Resistance ignites innovation.”   This is certainly an appropriate opening for Patriots’ Day 2025. For over 250 years, Massachusetts has led the way. We must continue to do so, and for MassBio, that means standing up for science, innovation, and the needs of patients. This is the place. Let’s fight for it.   Good luck to all the Boston Marathon runners who are putting their bodies to the test in support of so many incredible causes.   #PatientDriven #revolutionary #thisistheplace

Celebrating a partnership built on trust, expertise, and a vision for the future, MassBio and Veolia North America have announced an expanded partnership to accelerate efforts to make the biotech industry more environmentally sustainable. For over 20 years, Veolia North America has served as MassBio’s primary partner for meeting the waste management needs of our members, developing a strong track record for safety and customer service. “As the world’s leading environmental services company, Veolia is proud to support MassBio and the important work being done by their member companies to revolutionize healthcare and the sciences,” said Bob Cappadona, President and CEO of Veolia North America’s Environmental Solutions and Services business. Jason Cordeiro, chief operating and innovation officer at MassBio, was recently in Paris with the Veolia team for their annual Inspiration Days convening, speaking at length about how this partnership has significantly benefited the Massachusetts life sciences industry to the tune of $100 million in member savings. Read the announcement (https://lnkd.in/gHcaDVa7) and visit the Veolia #MassBioEdge preferred partner page: https://lnkd.in/gZxHN3eS.

Recorded at the SCbio annual conference, Kendalle joined co-hosts Matthew and Lauren for a wide-ranging conversation, including discussing how #MassBioDrive and #SCbioDrive are accelerating early-stage companies and supporting founders. Watch the full episode: https://lnkd.in/eSrk_89v. #PatientDriven

📢 #MassBioMembers: join our Community Celebration at BIO 2025! We are celebrating 40 years of innovation and community at a special event during the 2025 BIO International Convention. On June 17, join us at Cisco Brewers Seaport for an unforgettable night of music, networking with industry peers, and celebrating the achievements of the local life sciences! We are holding this event in lieu of our annual Summer Mixer. 👉Registration is now open: https://lnkd.in/er84Mf27 Sponsorship opportunities are available: https://lnkd.in/eswVbgm8 Contact Colleen Bellotti: https://lnkd.in/e9V_raDh

BioversityMA, a workforce training nonprofit and MassBio initiative, is hosting their marquee annual event – Celebrate Bioversity! – on May 8 at Southline Boston. We invite you to be inspired and hear from Bioversity graduates and students about their training and how life has changed for them as they start their new careers in the #lifesciences. Buy a ticket today to Celebrate Bioversity! - https://lnkd.in/eajZYYnY Make a donation to Bioversity: https://lnkd.in/eN6VWXGY Bioversity Inc. is a 501c3 public charity. All ticket purchases and donations to Bioversity are fully tax deductible.

If you are the CEO of a biotech that engages with the FDA, please take this very short survey MassBio is conducting in partnership with Biocom California: https://lnkd.in/eiPXX9Yr. Dramatic changes at the FDA could drastically interrupt the drug development pipeline and approval process. Collecting real-time data on the impacts of these cuts on companies working to bring new drugs to market is essential. This information will be used to inform policymakers of the challenges these changes are creating and the potential impacts on patients. Though this survey pertains only to FDA, MassBio is committed to understanding the full scale of the impacts from policy, funding, and staffing changes at the federal level. Our biggest priority remains maintaining the flow of medicines to patients, a process that stretches from academic discovery and R&D to manufacturing and access. #FDA #drugapproval #drugdevelopment Photo Credit: JHVEPhoto via BigStockPhoto. This survey is not affiliated with any U.S. government agency.

MassBio will join AMG World and industry leaders from Regeneron, Moderna, Pfizer, Sanofi, Takeda, and more at the 5th Annual Future Labs, Automation & Technology East on May 20. We're looking forward to this intimate, discussion-driven event designed to help #lifesciences organizations leverage disruptive technologies, scale innovation, and digitally optimize lab space. Register using our exclusive discount code PARTNER15 to receive 15% off your pass: https://lnkd.in/e4Cawhgk and check out the full event agenda here: https://lnkd.in/ejQ9QKeC We look forward to seeing you there! #AMGWorld #FutureLabsSummit #LabOfTheFuture #DigitalLab #LabAutomation

Last year, nearly 500 leaders, educators, and innovators came together to strategize on building a strong, diverse life sciences workforce for the long term. This year, we’re looking ahead: How do we prepare today’s talent for a technology-enabled future? Join the conversation on June 3 at Boston University: https://ow.ly/sMuO50VBMkK #LSWC25 #Conference #LearningandDevelopment #Biotech #Massachusetts

MassBio and the companies we represent will work with all policymakers across the federal landscape to share our knowledge and shape, as best as possible, a positive outcome that unleashes American innovation and extends patient access to the groundbreaking medicines this industry develops. Read Kendalle's full statement: https://lnkd.in/eJMMdCTy.

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Spring 2025 Cohort last month, and are highlighting our five emerging biotech companies chosen to participate. Meet Interactome Biotherapeutics! Q: Can you tell us about your company and the innovation you’re bringing to the biotech space? A: Extracellular Vesicles (EVs) are an emerging paradigm in non-viral delivery. Over the last 17 years, we have spent time, effort, and resources developing know-how, trade secrets, and intellectual property to be in the forefront of these tailwinds as follows: - CMC, Bioprocess know-how, trade secrets, and pending patents related to scalable, consistent, and high-level QC of Progenitor Cell EVs. - Protecting our pipeline and compounds with a growing moat of patent claims focused on organ-specific diseases and targeted EV MOA. - Protecting our EV Engineering Platform and executing Biopharma partnerships that target organ-specific diseases in novel and commercially advantageous ways. Q: What excites you most about your progress? A: - Our success in producing regulatory and commercial grade EV products. - That our results have drawn collaborators from the very pinnacle of the EV field. - Our good fortune in being at the front of the second wave of this field after the giants of pharma failed to accomplish what we, with our methodical and stringent approach, can bring to the table. Q: What key lessons or insights would you share with early-stage biotech founders navigating their startup journey? A: Focus on people, not things. As has been said, “find good people and leave them alone.” Shield them from problems and external hurdles whenever possible. Celebrate success and turn failure into opportunity. Success and loyalty will follow. Q: How has your experience with the MassBioDrive program shaped your perspective or impacted your company’s growth since joining the program? A: This program has given our team the validation and the maypole that we have been seeking. Although our strategy made sense, we needed a center around which to organize our company. Exposure to the MassBio ecosystem, the INCREDIBLE modules, the mentors and interactions with the professionalism of the MassBio staff have elevated our self-image and sense of responsibility to the job at hand. Learn more about Interactome: https://lnkd.in/eGAYTJAp Learn more about MassBioDrive: https://lnkd.in/eAztxEdd